首页> 外文期刊>Biomarkers >IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk
【24h】

IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk

机译:Barrett食道及相关食道腺癌发生过程中IGFBP-3和IGFBP-10(CYR61)的上调:潜在的疾病危险生物标志物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Dys-regulation of the insulin-like growth factor (IGF) system increases the risk of a number of malignancies. The aim of this study was to investigate the role of members of the IGF binding protein (IGFBP) superfamily in the development of oesophageal adenocarcinoma (EAC) and their possible use as markers of disease risk. Expression of IGFBP-2, IGFBP-3, IGFBP-4, and IGFBP-10/CYR61 was assessed using Real-Time-polymerase chain reaction (PCR) and immunohistochemistry in oesophageal tissues from Barrett's oesophagus (BE) patients with and without associated EAC, and in control subjects. IGFBP-3, IGFBP-4, and IGFBP-10/ CYR61 mRNA levels were up-regulated in Barrett's (n = 17) and tumour tissue of EAC patients (n = 18) compared with normal tissue of control subjects without BE or EAC (n = 18) (p < 0.001). Over-expression of IGFBP-3 and IGFBP-10/CYR61 proteins was observed in Barrett's, dysplastic and tumour tissue of EAC cases (n = 47 for IGFBP-10; n = 39 for IGFBP-3) compared with adjacent normal epithelium (p < 0.050). Notably, IGFBP-3, IGFBP-4, and IGFBP-10/CYR61 expression in Barrett's tissue of EAC cases (n = 17) was significantly (p < 0.001) higher than in Barrett's tissue of BE patients with no sign of progression to cancer (n = 15). Overall, the results suggest that members of the IGFBP superfamily are up-regulated during oesophageal carcinogenesis and merit further investigation as markers of EAC risk.
机译:胰岛素样生长因子(IGF)系统的调节异常会增加许多恶性肿瘤的风险。这项研究的目的是调查IGF结合蛋白(IGFBP)超家族成员在食管腺癌(EAC)发生中的作用及其可能用作疾病风险标记。使用实时聚合酶链反应(PCR)和免疫组织化学方法评估Barrett食管(BE)有无EAC的患者食道组织中IGFBP-2,IGFBP-3,IGFBP-4和IGFBP-10 / CYR61的表达,以及对照对象。与没有BE或EAC的对照组相比,EAC患者的Barrett(n = 17)和肿瘤组织(n = 18)中的IGFBP-3,IGFBP-4和IGFBP-10 / CYR61 mRNA水平上调。 n = 18)(p <0.001)。与邻近的正常上皮相比,在EAC病例的Barrett's,增生异常和肿瘤组织中观察到IGFBP-3和IGFBP-10 / CYR61蛋白的过表达(IGFBP-10,n = 39; IGFBP-3,n = 39)。 <0.050)。值得注意的是,EAC病例的Barrett组织(n = 17)中的IGFBP-3,IGFBP-4和IGFBP-10 / CYR61的表达显着(p <0.001)高于没有癌症进展迹象的BE患者的Barrett组织。 (n = 15)。总体而言,结果表明,IGFBP超家族成员在食道癌变过程中被上调,值得进一步调查,以作为EAC风险的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号